Author: admin

A test of blood offered by Instant viral discrimination for three major viruses received the CE mark.

|

A test of blood offered by instant for three major viruses malware, discrimination received the CE mark.

-test cobas TaqScreen r MPX, v2.0 (1) provides results in real time for HIV, HCV and HBV

Pleasanton, California, may of 2011. Roche (SIX: RO, ROG;) OTCQX: RHHBY) announced last Monday that the cobas TaqScreen r test MPX, version 2.0 for use in the system cobas s 201, already available in Europe estácomercialmente

This latest version of the test widely used (R) cobas TaqScreen MPX provides an increase in the sensitivity and is the only commercially available test that provides a simultaneous resolution of viral objective in the automated system, eliminating the need for more tests, with the time that brings about positive units.

This test is a qualitative test in vitro for the direct detection of the virus of human immunodeficiency type 1 group M RNA, HIV-1 Group O RNA, HIV type 2 (HIV-2) RNA, hepatitis C (HCV) RNA virus and hepatitis B (HBV) DNA in human plasma virus (HIV-1). It is provided for the use of the test for show control of donations of blood components complete human and of blood components, including source plasma.

“Roche is the market leader worldwide in sites of donations with tests and tests”, said Paul Brown, responsible for Roche Molecular Diagnostics, the business area of Roche has developed the test. “To develop continuously innovative products are improving the highest level of safety of blood for patients and the effectiveness of the centres of blood.” “This test brings us a step closer to achieving these objectives”.

As a result of the process of Roche global control of the viral genome databases to track the changes that might occur in the viral sequences, trial has reformulated in order to include all recent viral sequences that are possible, increasing the range of the viral targets including.

The cobas TaqScreen r test MPX, v2.0 also offers an efficiency increase in blood centers to eliminate the need for some evidence of viral discrimination, reducing the volume of required samples and the delivery time of the testing of donor. To use the technology in real-time from multiple PCR tinctures, results are detected simultaneously and discriminate HIV, HCV and HBV for specimens individual, eliminating the need for discriminatory test additional time attendant and other commercially available tests.

The test works within the fully automated cobas s 201, which is designed to enhance the effectiveness of prosecution in a modular design with ready to use reagents. Many tinctures technology allows the detection of signals in four separate channels, providing simultaneous control of three viral targets (HIV, HCV and HBV) as well as an internal control of all processes.

In addition to HIV, HCV and HBV, the menu system-cobas s 201 includes tests for the virus in the Western Nile, parvovirus B19 (B19V) and virus hepatitis A (HAV) (2). All control of blood of Roche test based on technology of acid nucleic (NAT), which offers a primary detection of virus from traditional serology tests. System cobas s 201 offers NAT more thorough test available within a single platform automated menu.

On the control of blood and plasma Roche

Roche is leader in the global market for control of blood and plasma NAT, which is estimated to have a value of nearly 800 million Swiss francs. Nucleic acid-based tests enable the primary detection of viral infections with conventional antibody or Antigen tests. Trials of nucleic acids in real time based on PCR Roche used since 1998 for controlling blood and plasma products. There are currently more than 250 blood banks in the world that use the automated cobas s 201 Roche.

about Roche

with headquarters in Basel (Switzerland), Roche is a world leader in health focusing on pharmaceuticals and Diagnostics and a fortress combined in pharmaceuticals and Diagnostics. Roche is the largest global company in biotechnology drugs truly differentiated in Oncology, virology, inflammation, metabolism and CNS. Roche is also a world leader in Diagnostics in-vitro, diagnosis of cancer based on tissues and pioneered treatments against diabetes. Personalized health Roche strategy aims to provide medicines and tools of diagnosis to enable tangible improvements in the health, quality of life and survival of patients. In the year 2010, Roche had over 80,000 employees around the world, investing more than 10 billion Swiss francs in r & d. The Group achieved sales of 49.100 million Swiss francs.

Genentech, United States, is a complete affiliate member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.


–
referencia:

(1) this product has not received approval or available for use in United States.

(2) The double test for B19V and hav been completed according to the FDA through a Drug Master File. It is available for laboratories of United States that meet the specific demands of the FDA.

Read More

“In the future we can waive chemotherapy”.

|

“ In the future we can dispense with chemotherapy ”.

international Diada XXXV of the Catalan society of Haematology and haemotherapy in the Medical Sciences Academy i la Salut de Catalunya i Balears.

-linked to drugs or radioactive products monoclonal antibodies will allow increase the antitumor effectiveness. These new combinations, targeting specific therapeutic targets, can be possible that in the future can be spared chemotherapy

-these antibodies have meant a revolution in the field of Hematology. probably are the most important advance in the treatment of lymphoproliferative symptoms since the 1970s

– one of the most important presences has been that of the DRA. Anita Hill, one of the main researchers of the study which has shown that patients with paroxysmal nocturnal hemoglobinuria (PNH) who receive treatment with eculizumab have an index similar to that of the general population survival

Barcelona, 2011-June “ is possible that in the future can dispense with chemotherapy through combinations of drugs targeting specific therapeutic targets and monoclonal antibody ”said Dr. Armando López-Guillermo of the Hospital Clínic of Barcelona and Coordinator, along with the Dr. Francesc Bosch of the Hospital Vall d ’ Hebron, of the XXXV international day of the Catalan society of Haematology and haemotherapy in the Medical Sciences Academy i la Salut de Catalunya i Balears.

“ Therapeutic possibilities open with the antibody monoclonal (AcMo) are huge ”, pointed out Dr López-Guillermo, and “ is being carried out clinical trials to test the effects of the AcMo linked to drugs or radioactive materials which would increase the antitumor efficiency ”. However, currently only 4 or 5 AcMo are marketed and are commonly used in hospitals and only one of them, Rituximab, used in a massive way.

Monoclonal antibodies have meant a great step for the field of Hematology. These have brought a revolution in the treatment of lymphomas, which resulted in the improvement of the survival of patients. “ Have probably been the most important advance in the treatment of lymphoproliferative syndromes, particularly lymphomas hodgkinianos, since the advent of chemotherapy in the 1970s ”, explained Dr. López Guillermo. In fact, in the field of Hematology, has been a specific monoclonal which has achieved important results, rituximab (anti-CD20).

For what it does to the detection and treatment of leukemia, monoclonal antibodies still do not have a prominent role. In chronic lymphatic leukaemia rituximab has also proved to be an effective drug. Globally, the Dr. Guillermo López stated that “ have to wait and see whether the new generations of AcMo are much more active in all lymphomas ”.

Another important monoclonal antibody is eculizumab, used in the treatment of patients with PNH (paroxysmal Paroxística night), one of the so-called rare diseases affecting about 250 patients in all Spain. The DRA. Anita Hill, Hospital Universitario St. James of Leeds (England), has been commissioned to speak during the day, since it is one of the leading researchers in a study that shows that PNH patients who receive treatment with this medication orphan have a rate similar to that of the general population survival and less risk of complications. The great benefit of this monoclonal is to reduce chronic intravascular hemolysis, underlying cause of morbidity and mortality from this disease, so that it substantially improves the quality of life of patients.

Information about the Academy:

The Academy of medical sciences and the health of Catalonia and Balears is an entity founded in 1872, with legal personality recognised officially, and constitutes a forum and a meeting place of professionals in the health of Catalonia, the Balearic Islands, Valencia and Andorra. It is an institution independently of the service of countries and not linked to any official body.

Its purpose is to promote the study and the cultivation of the Sciences of health in all its aspects: human, technical, social and civic, from all its aspects: health care, teaching and research

It is a lively scientific community, the collective effort that adapts to the needs and scientific circumstances at the time, working in collaboration with other medical, biological and pharmaceutical, domestic and foreign companies, with a constant concern of progress.

It is the most important medical Corporation of Catalonia, by the number of partners, more than 22,000. It is composed of 76 scientific societies that bring together professionals in the health sciences. Annually, the volume of scientific activities undertaken jointly is higher than 3000 acts and professionals who exceed the figure of 42,000 people.

It is present in all of Catalonia, Balearic Islands, Valencia and Andorra through its subsidiaries, and their special characteristics, fruit of the momentum of civil society, can be considered that it is an institution unique in the world.

Read More

Health option helps doctors affected by incompatibility decreed by the Ministry of labour.

|

health option helps doctors affected by incompatibility decreed by the Ministry of labour.


– the Ministry of health exempt them from the obligation to give his intention to retire to.

-la Council rejects the measure taken by the Ministry of labour and immigration.


Spain, June of 2011- the Ministry of health of the Madrid has issued a resolution through the human resources management for professionals in the system public Madrid opt for retirement during the month of June will not have to apply for three months in advance as established in the resolution of November 2004. The suspension has its cause in the Ministry of labour and immigration has issued an order published the last May 26, 2011 on the incompatibility of the perception of the retirement pension scheme with the activities carried out on their own by the professional collegiate.

this order establishes the incompatibility which will take effect from next July 1. The Ministry of health has deemed it appropriate to adopt this standard in order to facilitate to concerned practitioners who are able to exercise their right to retire before the action taken by the Ministry of labour and immigration.

the Ministry of health of the Madrid criticized the entry into force of this rule and has asked the Ministry of labour and immigration that assess the impact of such implementation, which can cause damage both to practitioners affected for the Organization of services health.

the Ministry of Health believes that more than 100 doctors ask the retirement during the month of June in order to thus collect the Social Security pension and to continue its activity by account itself.

Read More

Locals were more than 80,000 blood donations the first 5 months of the year.

|

locals were more than 80,000 blood donations the first five months of the year

more blood … more life is the motto of the international day of the donor’s blood which was held yesterday 14 of June.



– an increase of 3.1% over the same period in the previous year.

-transfusion Center c elebra an open day to publicize the process that follows the blood.



Spain, 2011-June during the first five months of 2011 Madrid have made a total of 80.316 blood donations, an increase of 3.1% compared to those recorded in the same period of the previous year. This was stated the Director Manager of the Center, Dr. light Barbolla, opening day of doors open to all citizens.

last Tuesday, June 14 was the blood donor international day, chance that the community take this opportunity to thank, once again, the generosity of citizens. Thanks to it the hospitals in the region were 284.626 transfusion of blood components during 2010, essential for a multitude of medical treatments and surgical.

this edition of the international day of the donor, for which the World Health Organization has chosen the motto “ more blood … more life ”, will feature celebrations around the world and, especially, in Argentina, country selected as World Headquarters on this occasion.

the goal of today is to inform the people of Madrid the process that follows the blood from the donation until sent hospitals. So visit the room of donation, area of fractionation on the different components (red blood cells, platelets and plasma), conservation, laboratories, storage and transport systems.

transfusion Center is located on the Avenue of democracy, without number, in Valdebernardo. Access by public transport can occur through the line 9 metro stop Valdebernardo, and 8, 71, and 130 bus lines.

on this occasion, from the transfusion centre you wish to make a special recognition to professionals in hospitals, through donation, marathons have contributed more than 4,000 donations in the past year, with a high rate of participation, which demonstrates his sensitivity to the need for components and derivatives of the blood.



update on the stocks of blood.

transfusion Center maintains the content about donation in the Madrid Community Health Portal. Thus, citizens can know through www.madrid.org/donarsangre, the updated position of the reserves of blood in the community, as well as points and schedules of donation, among other data.

to donate blood there is no special requirements, only to be willing to donate. Any person with a normal health, 18 years of age or older and less than 65 can donate if it weighs more than 50 kg. To facilitate the donation the Ministry of health has units of donation in the region public hospitals, in the very center of transfusion Valdebernardo, in the unity of the Puerta del Sol and the mobile units which daily move through different parts of our community.


Read More

Lack of money for research endangers the attention to the patient.

|

The lack of money for research endangers the attention to the patient.

-European specialists in hematology to trigger the alarm

London, 2011- June/PRNewswire /. The European Hematologists fire alarms about the lack of money for research for blood disorders. “Leukaemia kills more than 95,000 people in Europe every year;” “The EU offers few opportunities for the Hematologists to finance his research,” said Dr. Robin Foa, director-general of the European Hematology Association (EHA) at its annual Congress in London. Last Friday, June 10, the European Commission ended the process of consultation on the forthcoming EU research programme. EHA asks for help to the Commission to consider more opportunities for funding for the Hematology program.

“Not only are disorders blood such as anemia, coagulation and haemophilia diseases more expanded in Europe, blood cancers kill more than 95,000 people in the EU each given year. the impact on the health of Europeans, especially the young and the elderly””, it is surprising how few resources are made available by the European Commission for haematological research,” said Foa.

The research of the Hematologists is responsible for major scientific advances in research of cancer, personalized medicine and stem cell have found applications in many other disciplines such as Oncology, cardiology, immunotherapy or even the Rheumatology or organ transplantation. Researchers in hematology are also excellent in translational research, quickly leading the laboratory results to clinical practice. “For example, the main role of objective therapy in Oncology comes revolutionary haematological research on leukemia which changed the natural course of disease.” “I have the impression that the Commission is not aware of our excellent record to continue and enhance the leadership position that European Hematology possesses globally,” he argued, Foa.

EHA, European representative of the medical specialists in the field of blood disorders, currently holds its Conference. In its response to the consultation, the EHA calls on the Commission to create more opportunities for funding in hematology in its next programme of research.

EHA is an NGO that promotes excellence in clinical practice, research and education in the European hematology. EHA represents the Hematologists of Europe (more than 3,000 members, more than 9,000 participating Hematologists in Congress, and the main publication in Europe, Haematologica/The Hematology Journal. Hematology

–
fuente:

WHO (2008).) The global burden of disease.

ECO. International Agency for Research on Cancer.

Read More

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips